Background
An estimated 25 million adults in the United States suffer from daily pain, and another 23 million have severe, recurrent pain. Persistent pain causes disability, loss of productivity, lower quality of life, and overall poor health. 1 There has been a steady increase in the number of opioid prescriptions in the past few decades to manage pain. It is now estimated that the number of annual prescriptions for opioids is approximately equal to the number of adults in the country. 2, 3 Rates of adverse effects of opiate medications, the primary concerns being addiction and overdose, 4 have concomitantly increased with prescription opioid use. As a result, an average of 115 individuals die daily in the United States from opioid overdose. 5 Patients who abuse or are dependent on prescription opioids are 40 times more likely to use or abuse heroin compared to those who take opioids as prescribed and have no dependency issues. It is estimated that 4% of prescription opioid users are expected to become heroin users. 6 While the hypothesis that marijuana may substitute for opioids exists, there is a concurrent hypothesis that opioid and marijuana use are not mutually exclusive and may be co-occurring. For example, an increase in opioid use/abuse may be associated with an increase in marijuana use. One study reported co-occurring marijuana use to be 13.2% among nonopioid users, 18.3% among prescription opioid users, 40.1% among prescription opioid misusers, 39.9% among those with prescription opioid use disorder, and 58% among heroin users. 7 In response to the opioid crisis, the U.S. Food and Drug Administration (FDA), among other medical and public health organizations, has attempted to identify strategies to curb this epidemic. Marijuana is reported to be an effective method to relieve pain, 8, 9 and authors of a systematic review of the literature concluded that there are data, though limited, suggesting an association between medical cannabis and a reduction in mortality associated with prescription opioid use. 10 As of 2015 (the cutoff year for data used in the analyses of this study), there were 23 states that had legalized medical marijuana. As of 2016, 31 states had legalized medical marijuana; among these 31, 8 states plus Washington, DC, also had legalized recreational marijuana. 11 Almost two decades after the initiation of individual state-led legalization of medical marijuana, there is mixed evidence regarding the impact of marijuana on opioid-related mortality rates. To that end, the objective of this clinical inquiry (Clin-IQ) project is to explore if a state's decriminalization of marijuana, whether medical or recreational, can attenuate the opioid crisis.
Methods
We searched Ovid MEDLINE, Ovid MEDLINE In-Process, PubMed, and Embase using the search terms marijuana, cannabis, legal, marijuana smoking, medical marijuana, opioid-related disorders, cannabis use, medical cannabis, legal aspect, and opiate addiction. Studies of animals, injectable drugs, and cannabidiol (commonly referred to as CBD) were excluded. We included articles published from January 1, 2012, through December 5, 2018; however, we limited marijuana-related data to 2015 or prior and opioidrelated data to 2016 or prior to allow a minimum of 1 year to elapse between marijuana decriminalization and subsequent measures of opioid use. Surveillance data for opioid use were not complete for years 2017 and beyond at the time this study was conducted. Table 1 summarizes the reviewed literature, which included 1 retrospective cohort study, 3 cross-sectional studies, and 6 ecologic studies using aggregate data.
Summary of Evidence
The retrospective cohort study accessed data from the National Epidemiological Survey on Alcohol and Related Conditions, which assessed associations between cannabis use and 1) prevalent opioid use, 2) incident opioid use, and 3) prescription opioid use disorder. 12 This data set included a measure of patients' chronic pain. Investigators reported that cannabis use was associated with greater opioid use as defined by these outcomes. 12 The highest quality of the cross-sectional studies used data collected from the National Survey on Drug Use and Health, which is sponsored by the U.S. Substance Abuse and Mental Health Services Administration. 13 Selfreported marijuana use was compared to self-reported use of prescription pain killers, from 2004 to 2012 in 10 states. No significant association was observed in either adolescents (age 12-20 years) or adults (age 21+ years). 13 The other two cross-sectional studies were based on convenience samples and investigated cannabis use as a substitution for opioids. Corroon 15 Of respondents who reported regular use of opioid pain medications (n=215), more than three-quarters (76.7%) reported a reduction in opioid use after starting medical marijuana, supporting marijuana use as a substitution for pain medication. This study was conducted only in states where marijuana had been decriminalized; therefore, the impact of legal marijuana use cannot be assessed in the absence of a control group. In addition, multiple authors of this study had previous or hold current employment in cannabis dispensaries, presenting potential conflicts of interest. 15 Both of these studies had limitations related to selection bias, convenience sampling, and survey design.
Authors (Year) Objective Study Design Population, Data Collected Results, Conclusions
A 2016 study by Bradford and Bradford used 2010-2013 data of all prescription drugs covered under Medicare Part D to investigate the effects of medical marijuana laws on opioid-prescribing patterns. 16 Data included 9 medical conditions, including pain, that were mentioned in at least 4 states' medical marijuana laws and have at least 1 FDA-approved drug for off-label use. A bivariate analysis comparing "prescriptions filled in a state" and year of marijuana legalization resulted in 1826 fewer daily doses for pain medication filled per physician per year (P<0.01). To evaluate unobserved characteristics of general differences in prescribing behaviors between physicians in states with and those without marijuana laws, these results were compared with other drug categories for which marijuana has no clinical benefit (blood thinners, antibiotics, etc), and no difference was found. Primary weaknesses of this study included the ecologic study design and sample population consisting of only those ≥65 years of age and enrolled in Medicare Part D. 16 Bradford and Bradford conducted a subsequent study of similar design using Medicaid data and reported similar findings. 17 Another study used state-level Medicaid data to assess changes in prescription opioid use over time. 18 Prescription opioids were stratified into Schedule II (eg, hydrocodone and oxycodone) and Schedule III opioids (eg, codeine). Variables indicating the presence and time of enactment of statewide medical cannabis laws were included in the statistical analysis. The authors reported no association with decreased use of Schedule II opioids but a significant reduction in the use of Schedule III opioids in states that had decriminalized medical marijuana. It should be noted that Schedule II opioids account for approximately 95% of all prescription opioids; therefore, the overall impact of these reported associations is limited. 18 Powell et al employed a study design similar to that of Bradford and Bradford but which stratified states into categories based on the timing of adopting medical marijuana laws. 19 Using 2010 as a cutoff, states enacting medical marijuana legislation before 2010 were considered early adopters and those in 2010 or after were late adopters. States that did not have medical marijuana laws were never adopters. Primary results were mixed; late adopters were found to have the lowest opioid-related mortality rates, followed by never adopters. Early adopter states were found to have the highest opioid-related mortality rates. 19 In a 2017 ecologic study, Shi applied linear time-series regression analysis using State Inpatient Databases that included information from 27 states that met the inclusion criteria. 20 This study tested associations between the implementation of medical marijuana policies and rates of hospitalizations from 1997 to 2014 for opioid abuse/ dependence, marijuana abuse/dependence, and opioid-related overdose. Results showed an increase in marijuana and opioid-related hospitalizations in all 27 states by 300%, on average, during this time period. However, implementing medical marijuana policies was associated with reduction in hospitalization rates by 23% for opioid dependence or abuse (P=0.008) and 13% for opioid pain reliever overdose (P<0.05). Additional analyses with lagged effects were conducted, and when assuming a 1-year lag post-medical marijuana policy implementation, there was a 9.4% reduction in hospitalization rates for opioid dependence or abuse (P<0.05). However, no difference was observed for marijuana-related hospitalizations. Inconsistencies in data collection and coding practices were limitations of this study. 20 A 2014 ecologic study by Bachuber et al investigated the association of medical marijuana and opioid-overdose mortality in the United States using vital records. 21 Applying time-series analysis, the authors compared opioid-overdose mortality rates between all 13 states that had medical marijuana laws effective prior to and during 1999-2010 and those that did not have medical marijuana policies. Results showed a 24.8% lower mean annual opioid-overdose mortality rate (95% CI: -37.5% to -9.5%; P=0.003) in states with the uptake of marijuana laws compared to states without marijuana laws. This association strengthened over time. The primary weakness of this study is its ecologic/aggregate study design precluding information about medical use among fatal overdose decedents. 21
To supplement the published literature, we accessed data on the prevalence of opioid prescriptions per 100 population and opioid-related overdose mortality rates per 100,000 population for 2016 from the National Institutes of Health/National Institute on Drug Abuse. 22,23 Tables 2 and 3 23 These findings stem from a crude analysis using ecologic/aggregate study design; therefore, overall impact and interpretation is limited.
Given that state-level data are ecologic and the person-level data are drawn from convenience samples, these data serve to generate hypotheses rather than establishing causal relationships. This field is rapidly changing because of policy implications. For example, clinical practice may have changed as a result of the U.S. Centers for Disease Control and Prevention guidance on the prescribing practices of opioids. 24 Using the Strength of Recommendation Taxonomy (SORT) criteria by Ebell et al, the level of evidence to support the hypothesis that opioid use decreases among states where marijuana use has been decriminalized is level B ("recommendation based on inconsistent or limited-quality patient-oriented evidence"). 25 Additional epidemiologic studies at the patient level (especially cohort studies) are needed to better understand the impact decriminalizing marijuana use has on opioid abuse.
Conclusions
With the ongoing opioid epidemic, it is critical to scrutinize medical marijuana as a substitute for pain medications in terms of its analgesic properties and potential harm. Based on this literature review, there is mixed evidence regarding the impact of marijuana legislation and prescription opioid-related outcomes.
Eight studies provided evidence of reductions in the rate of opioid overdose, opioid-related hospitalizations, number of narcotic pain prescriptions written, and patient-reported substitution of marijuana for opiates, in states with medical marijuana laws. However, the one patient-level study reported an actual increase in opioid use among cannabis users. Data from the National Institute on Drug Abuse also indicated states with medical marijuana laws had higher rates of opioid-related overdose deaths. In addition, the variability across study design, measures of opioid abuse, and measures of marijuana use in the reviewed studies contributes to the challenges in identifying a consistent pattern in the results.
Given these mixed results, more robust studies in which patients are followed prospectively to measure the association between cannabis use and opioidrelated outcomes are sorely needed to determine the impact of marijuana legislation on opioid use and abuse. 
